Three Georgia companies and their principals have been banned from continuing their "bogus claims" that their stem cell ...
The substantial data supporting platelet-rich plasma (PRP) therapy and exosomes for androgenic alopecia have yet to convince ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...
Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes.
Dr Tsun Sean Law details the ARISE trials and outlines other orthobiologic treatments currently available — but not yet ...
A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...
Allogeneic stem cell therapy allows "off the shelf" cells ... Presuming that EU approval can be secured, the next major milestone will be FDA approval. In March this year the company received ...
Stem cell therapy aims to reboot the immune system and prevent MS attacks. Though it shows promise and is available through clinical trials, it’s not FDA-approved to treat MS. If you’re ...
A federal court has banned the co-founders of the Stem Cell Institute of America and associated entities from marketing stem ...
But the FDA has granted approval based on findings of the Phase 1b/2 GO29365 study in people with R/R DLBCL who are ineligible for a haematopoietic stem cell transplant. Results of the study ...